A Hillary Steinhart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
A Hillary Steinhart has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Alain Bitton
Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada
2 shared publicationsBrendan Halloran
Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada
2 shared publicationsBrian Bressler
Department of Medicine, Division of Gastroenterology, St Paul's Hospital, Vancouver, British Columbia, Canada
2 shared publicationsChadwick Williams
Division of Digestive Care & Endoscopy, Department of Medicine, Dartmouth General Hospital, Halifax, Nova Scotia, Canada
2 shared publicationsCharles N Bernstein
Section of Gastroenterology, University of Manitoba, Winnipeg, Manitoba, Canada
2 shared publicationsCynthia H Seow
Departments of Medicine & Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
2 shared publications
Latest Publications
- Open Access
- 14 September 2018
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 1 (4) , 141-154
Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto Consensus
Fistulas occur in about 25% of patients with Crohn’s disease (CD) and can be difficult to treat. The aim of this consensus was to provide guidance for the management of patients with perianal fistulizing CD. A systematic literature search identified studies on the management of fistulizing CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform using a modified Delphi process, then finalized, and voted on by a group of specialists. The quality of evidence for treatment of fistulizing CD was generally of very low quality, and because of the scarcity of good randomized controlled trials (RCTs), these consensus statements generally provide conditional suggestions (5 of 7 statements). Imaging and surgical consultations were recommended in the initial assessment of patients with active fistulizing CD, particularly those with complicated disease. Antibiotic therapy is useful for initial symptom control. Antitumor necrosis factor (anti-TNF) therapy was recommended to induce symptomatic response, and continued use was suggested to achieve and maintain complete remission. The use of concomitant immunosuppressant therapies may be useful to optimize pharmacokinetic parameters when initiating anti-TNF therapy. When there has been an inadequate symptomatic response to medical management strategies, surgical therapy may provide effective fistula healing for some patients. Optimal management of perianal fistulizing CD requires a collaborative effort between gastroenterologists and surgeons and may include the evidence-based use of existing therapies, as well as surgical assessments and interventions when needed.
- 14 September 2018
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 1 (4) , 141-154
Open AccessClinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto Consensus
Fistulas occur in about 25% of patients with Crohn’s disease (CD) and can be difficult to treat. The aim of this consensus was to provide guidance for the management of patients with perianal fistulizing CD. A systematic literature search identified studies on the management of fistulizing CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform using a modified Delphi process, then finalized, and voted on by a group of specialists. The quality of evidence for treatment of fistulizing CD was generally of very low quality, and because of the scarcity of good randomized controlled trials (RCTs), these consensus statements generally provide conditional suggestions (5 of 7 statements). Imaging and surgical consultations were recommended in the initial assessment of patients with active fistulizing CD, particularly those with complicated disease. Antibiotic therapy is useful for initial symptom control. Antitumor necrosis factor (anti-TNF) therapy was recommended to induce symptomatic response, and continued use was suggested to achieve and maintain complete remission. The use of concomitant immunosuppressant therapies may be useful to optimize pharmacokinetic parameters when initiating anti-TNF therapy. When there has been an inadequate symptomatic response to medical management strategies, surgical therapy may provide effective fistula healing for some patients. Optimal management of perianal fistulizing CD requires a collaborative effort between gastroenterologists and surgeons and may include the evidence-based use of existing therapies, as well as surgical assessments and interventions when needed.
- Open Access
- 6 August 2018
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 25 (1) , 1-13
Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto Consensus
Fistulas occur in about 25% of patients with Crohn’s disease (CD) and can be difficult to treat. The aim of this consensus was to provide guidance for the management of patients with perianal fistulizing CD. A systematic literature search identified studies on the management of fistulizing CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform using a modified Delphi process, then finalized, and voted on by a group of specialists. The quality of evidence for treatment of fistulizing CD was generally of very low quality, and because of the scarcity of good randomized controlled trials (RCTs), these consensus statements generally provide conditional suggestions (5 of 7 statements). Imaging and surgical consultations were recommended in the initial assessment of patients with active fistulizing CD, particularly those with complicated disease. Antibiotic therapy is useful for initial symptom control. Antitumor necrosis factor (anti-TNF) therapy was recommended to induce symptomatic response, and continued use was suggested to achieve and maintain complete remission. The use of concomitant immunosuppressant therapies may be useful to optimize pharmacokinetic parameters when initiating anti-TNF therapy. When there has been an inadequate symptomatic response to medical management strategies, surgical therapy may provide effective fistula healing for some patients. Optimal management of perianal fistulizing CD requires a collaborative effort between gastroenterologists and surgeons and may include the evidence-based use of existing therapies, as well as surgical assessments and interventions when needed.
- 6 August 2018
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 25 (1) , 1-13
Open AccessClinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto Consensus
Fistulas occur in about 25% of patients with Crohn’s disease (CD) and can be difficult to treat. The aim of this consensus was to provide guidance for the management of patients with perianal fistulizing CD. A systematic literature search identified studies on the management of fistulizing CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform using a modified Delphi process, then finalized, and voted on by a group of specialists. The quality of evidence for treatment of fistulizing CD was generally of very low quality, and because of the scarcity of good randomized controlled trials (RCTs), these consensus statements generally provide conditional suggestions (5 of 7 statements). Imaging and surgical consultations were recommended in the initial assessment of patients with active fistulizing CD, particularly those with complicated disease. Antibiotic therapy is useful for initial symptom control. Antitumor necrosis factor (anti-TNF) therapy was recommended to induce symptomatic response, and continued use was suggested to achieve and maintain complete remission. The use of concomitant immunosuppressant therapies may be useful to optimize pharmacokinetic parameters when initiating anti-TNF therapy. When there has been an inadequate symptomatic response to medical management strategies, surgical therapy may provide effective fistula healing for some patients. Optimal management of perianal fistulizing CD requires a collaborative effort between gastroenterologists and surgeons and may include the evidence-based use of existing therapies, as well as surgical assessments and interventions when needed.
- Open Access
- 14 March 2018
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 24 (4) , 669-670
Exit Strategies for Biologic Therapy in IBD: Is It Too Soon to Stop?
The advent of biologic therapies, in particular tumor necrosis factor–alpha (TNFα) blockers, has resulted in a major change in the way Crohn’s disease and ulcerative colitis are managed. This has been, in part, due to the demonstrated efficacy of these agents both for induction therapy for patients with symptoms or complications that are due to active inflammatory disease and for maintenance therapy in those patients who have responded to induction therapy.1–5 In addition, there is evidence that these drugs can result in mucosal healing, which, in turn, has been associated with improved long-term outcomes such as reduced hospitalization and reduced surgery.6–9 When these drugs were first introduced approximately 18 years ago, there was hope that they could be used for short-term therapy to induce remission, and that remission would then be maintained with other more conventional therapies or that the biologic drugs could be used intermittently in an “on demand” basis for flares of inflammatory disease activity. Unfortunately, these strategies have proven ineffective and have been associated with significant risk of clinical disease relapse following drug discontinuation and high rates of antidrug antibody development.10–12 As a result, there has been a tendency to maintain patients who respond to anti-TNF therapy on treatment indefinitely. However, despite the comparatively good short- and long-term safety profile of anti-TNF biologics, there has been a persisting concern among many patients and some physicians regarding the cumulative risk of therapy extended over many years or even decades.13–15 Aside from potential long-term safety concerns, there is the additional consideration of the financial impact of biologic therapy. Compared with nonbiologic therapies used to manage IBD, biologic therapy is very expensive. Medication costs currently account for an increasingly large portion of the overall cost of treating IBD, and the cost of medications appears to have replace surgery and hospitalizations as the largest single driver of cost. As a result, there are both individual and societal cost pressures that dictate that we should reexamine the indefinite use of these drugs in IBD patients to determine if similar improvements in outcomes can be achieved with other less costly, and possibly safer, approaches to the use of biologic therapies.
- 14 March 2018
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 24 (4) , 669-670
Open AccessExit Strategies for Biologic Therapy in IBD: Is It Too Soon to Stop?
The advent of biologic therapies, in particular tumor necrosis factor–alpha (TNFα) blockers, has resulted in a major change in the way Crohn’s disease and ulcerative colitis are managed. This has been, in part, due to the demonstrated efficacy of these agents both for induction therapy for patients with symptoms or complications that are due to active inflammatory disease and for maintenance therapy in those patients who have responded to induction therapy.1–5 In addition, there is evidence that these drugs can result in mucosal healing, which, in turn, has been associated with improved long-term outcomes such as reduced hospitalization and reduced surgery.6–9 When these drugs were first introduced approximately 18 years ago, there was hope that they could be used for short-term therapy to induce remission, and that remission would then be maintained with other more conventional therapies or that the biologic drugs could be used intermittently in an “on demand” basis for flares of inflammatory disease activity. Unfortunately, these strategies have proven ineffective and have been associated with significant risk of clinical disease relapse following drug discontinuation and high rates of antidrug antibody development.10–12 As a result, there has been a tendency to maintain patients who respond to anti-TNF therapy on treatment indefinitely. However, despite the comparatively good short- and long-term safety profile of anti-TNF biologics, there has been a persisting concern among many patients and some physicians regarding the cumulative risk of therapy extended over many years or even decades.13–15 Aside from potential long-term safety concerns, there is the additional consideration of the financial impact of biologic therapy. Compared with nonbiologic therapies used to manage IBD, biologic therapy is very expensive. Medication costs currently account for an increasingly large portion of the overall cost of treating IBD, and the cost of medications appears to have replace surgery and hospitalizations as the largest single driver of cost. As a result, there are both individual and societal cost pressures that dictate that we should reexamine the indefinite use of these drugs in IBD patients to determine if similar improvements in outcomes can be achieved with other less costly, and possibly safer, approaches to the use of biologic therapies.